BioMed Research International / 2016 / Article / Tab 3

Research Article

Subclinical Hypothyroidism in PCOS: Impact on Presentation, Insulin Resistance, and Cardiovascular Risk

Table 3

Clinical and biochemical characteristics of SCH PCOS, euthyroid PCOS, and euthyroid control subjects.

SCH PCOS
()
(mean ± SD)
Euthyroid PCOS
()
(mean ± SD)
Euthyroid control
()
(mean ± SD)
value

Age (years)29.21 ± 5.926.37 ± 4.528.1 ± 3.9NS
BMI (Kg/m2)32.70 ± 4.930.91 ± 5.127.3 ± 4.70.01
Hypertension (%)7 (25.9)11 (16.17)5 (5.5)0.008
Hirsutism (%)25 (92%)51 (75%)4 (5%)0
Ferriman and Gallwey score20.91 ± 5.318.37 ± 4.98.21 ± 4.30.1
LH13.12 ± 7.611.39 ± 6.85.81 ± 3.70.02
FSH4.7 ± 1.94.8 ± 1.84.41 ± 1.9NS
LH/FSH ratio2.9 ± 0.52.7 ± 0.71.01 ± 0.29NS
Free T3 (pg/mL)2.42 ± 1.32.82 ± 1.33.73 ± 0.7NS
Free T4 (ng/dL)1.02 ± 1.01.23 ± 1.11.32 ± 1.6NS
TSH (mIU/mL)7.2 ± 3.53.1 ± 1.53.2 ± 1.2<0.01
Anti-TPO ab (IU/mL)139.54 ± 51.732.59 ± 5.119.34 ± 10.3<0.001
Free testosterone (pg/mL)23.09 ± 6.318.34 ± 7.912.2 ± 5.7<0.01
Estradiol (pg/mL)59.31 ± 18.663.83 ± 26.774.24 ± 29.26NS
Progesterone (ng/mL)2.5 ± 0.62.9 ± 1.27.4 ± 4.3NS
HOMA-IR4.2 ± 1.12.8 ± 1.41.8 ± 0.70.01
Total cholesterol (mg/dL)230 ± 29.6198 ± 23.1159 ± 24.80.01
Triglycerides (mg/dL)136 ± 21.3120 ± 16.784.3 ± 10.60.001
LDL Chol. (mg/dL)151 ± 17.3139 ± 12.6109 ± 20.40.02
HDL Chol. (mg/dL)37.4 ± 15.445.9 ± 9.660.3 ± 5.20.04

= NS between SCH PCOS and euthyroid PCOS, between SCH PCOS and euthyroid controls, and between euthyroid PCOS and euthyroid control group on post hoc analysis.
= NS between SCH PCOS and euthyroid PCOS group, = NS between SCH PCOS and euthyroid controls, and = NS between euthyroid PCOS and euthyroid control group on post hoc analysis.
between SCH PCOS and euthyroid PCOS group, between SCH PCOS and euthyroid controls, and = NS between euthyroid PCOS and euthyroid control group on post hoc analysis.
between SCH PCOS and euthyroid PCOS group, between SCH PCOS and euthyroid controls, and between euthyroid PCOS and euthyroid control group on post hoc analysis.